NCT01018966View on ClinicalTrials.gov

Study of Ixabepilone (BMS-247550) in Patients With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

March 31, 2005

Study Completion Date

April 30, 2005

Conditions
Solid Tumors
Interventions
DRUG

Ixabepilone

Lyophilized and solvent, IV, 10-50 mg/m2, Q3W, At least 1 cycle, (21 days)

Sponsors

Lead Sponsor

R-Pharm
All Listed Sponsors
lead

R-Pharm

INDUSTRY